Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
Public ClinicalTrials.gov record NCT01083602. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, Multi-center, Single Arm, Open Label Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is designed to assess the effectiveness of the combination of Panobinostat plus Bortezomib and Dexamethasone in patients with relapsed and bortezomib refractory Multiple Myeloma.
Study identification
- NCT ID
- NCT01083602
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 55 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2010
- Primary completion
- Jan 31, 2014
- Completion
- Jan 31, 2014
- Last update posted
- Dec 20, 2017
2010 – 2014
United States locations
- U.S. sites
- 13
- U.S. states
- 11
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California at Los Angeles | Los Angeles | California | 90095 | — |
| Stanford University Medical Center Division of Hematology | Stanford | California | 94305-5826 | — |
| H. Lee Moffitt Cancer Center & Research Institute | Tampa | Florida | 33612 | — |
| Emory University School of Medicine/Winship Cancer Institute Dept. of Winship Cancer Inst. | Atlanta | Georgia | 30322 | — |
| Georgia Regents University MedCollege of GA Cancer Ctr 2 | Augusta | Georgia | 30912 | — |
| Hematology/Oncology of the North Shore Orchard Healthcare Res. Inc. | Skokie | Illinois | 60076 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02115 | — |
| Somerset Hematology Oncology Associates Somerset Hema Oncol Assoc (2) | Somerset | New Jersey | 08873 | — |
| Montefiore Medical Center | The Bronx | New York | 10467 | — |
| Duke University Medical Center Dept. of DUMC (4) | Durham | North Carolina | 27710 | — |
| Vanderbilt University Medical Center, Clinical Trials Center Vanderbilt UMC | Nashville | Tennessee | 37212 | — |
| MD Anderson Cancer Center/University of Texas MD Anderson CC | Houston | Texas | 77030 | — |
| Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01083602, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 20, 2017 · Synced Sep 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01083602 live on ClinicalTrials.gov.